ChromoGenics announces the outcome of exercised warrants of series TO 6
The board of directors of ChromoGenics AB (publ) ("ChromoGenics" or the "Company") today announces the outcome of the exercise period for warrants series TO 6 (the "Warrants") that were issued in connection with ChromoGenics' rights issue of units that was announced on 17 May 2023 (the "Rights Issue"). The Warrants were subscribed to approximately 0.25 percent. In total, ChromoGenics will receive approximately SEK 51 thousand before issue costs. Within the framework of the Rights issue, ChromoGenics issued 240,222,962 Warrants. The Company has, following the Rights Issue, carried out a